OVERVIEW

The hallmarks of immune-mediated inflammatory diseases (IMIDs) result from the intricate interplay of cells, cytokines, and other components of the immune system. Similar pathology underlies related rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus, and giant cell arteritis. Understanding the immunopathology of these diseases is essential to understanding the mechanisms of action through which different medications exert their effects. Another emerging trend in rheumatology is the identification and management of immune-related adverse events (irAEs) associated with new cancer immunotherapies; however, providers lack experience in managing these conditions. Biosimilars are another possible new treatment option in IMIDs. In this educational activity, expert clinicians will discuss the latest on pathogenesis and treatments of IMIDs.

AGENDA

8:00 AM  Registration and Breakfast
8:30 AM  Introduction and Pretest
8:40 AM  Part 1: Immunology 101
         Leonard H. Calabrese, DO
10:10 AM Posttest and Question & Answer
10:25 AM Break
10:40 AM Part 2: Advances in Targeted Therapies
         Vibeke Strand, MD, MACR, FACP
11:55 AM Posttest and Question & Answer
12:10 PM Break
12:25 PM WORKING LUNCH
         Diet, Exercise, and Mindfulness in Rheumatic Diseases:
         Clinician and Patient Perspectives
         Leonard H. Calabrese, DO
1:10 PM Break
1:20 PM Clinical Cases With the Experts
         Moderated by Adam Brown, MD and Cassandra Calabrese, DO
2:20 PM Posttest and Question & Answer
2:40 PM Conclusion
TARGET AUDIENCE
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with IMIDs.

LEARNING OBJECTIVES
Upon successful completion of this activity, participants should be better able to:

• Describe the latest understanding regarding the integrated immune response and how it impacts patients with IMIDs.
• Examine common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
• Evaluate the mechanisms of cancer immunotherapies as they relate to both an antitumor response and the potential for autoimmunity to better manage patients with irAEs.
• Select treatment for patients with IMIDs based on the latest clinical evidence and patient characteristics.
• Educate patients on how diet, lifestyle, and environment can influence immune response and overall wellness.
• Communicate with patients on biosimilars to identify patients who may prefer a biosimilar over a reference biologic.

BYOD (Bring Your Own Device)
In an effort to reduce the handling of materials, we encourage you to bring your own device to view the electronic program book and slide presentations. Tablets and laptop computers are optimal; however, the technology is also compatible with smartphones. Charging stations will be available.

Note: The electronic program book platform operates on a closed network (login credentials will be provided on-site); you will not be able to access other Wi-Fi enabled applications while connected to the program book network unless data services are enabled. Data plan fees incurred for accessing applications outside of the electronic program book are not eligible for reimbursement.